Developing anti-gout medications that simultaneously reduce uric acid and exert anti-inflammatory effects is of interest for managing gout progression. Here, the authors employ a dual-target pharmacophore model to design derivatives of β-carboline-1-propionic acid and identify a drug candidate demonstrating potent uric acid-lowering activity in male hyperuricemia mouse models and mitigating NLRP3-mediated inflammation.
- Zhijiao Zhang
- Xiaoyu Shi
- Peng Zhan
